167 related articles for article (PubMed ID: 21530679)
1. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan.
Shen LJ; Chou H; Huang CF; Chou GM; Chan WK; Wu FL
Contemp Clin Trials; 2011 Jul; 32(4):485-91. PubMed ID: 21530679
[TBL] [Abstract][Full Text] [Related]
2. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.
Grossi F; Genova C; Gaitan ND; Dal Bello MG; Rijavec E; Barletta G; Sini C; Donato C; Beltramini S; Pronzato P; Porcile G; Boccardo F; Walzer S
Lung Cancer; 2013 Aug; 81(2):236-40. PubMed ID: 23648072
[TBL] [Abstract][Full Text] [Related]
3. Drug cost avoidance resulting from cancer clinical trials.
Bredin C; Eliasziw M; Syme R
Contemp Clin Trials; 2010 Nov; 31(6):524-9. PubMed ID: 20840876
[TBL] [Abstract][Full Text] [Related]
4. Incremental treatment costs in national cancer institute-sponsored clinical trials.
Goldman DP; Berry SH; McCabe MS; Kilgore ML; Potosky AL; Schoenbaum ML; Schonlau M; Weeks JC; Kaplan R; Escarce JJ
JAMA; 2003 Jun; 289(22):2970-7. PubMed ID: 12799405
[TBL] [Abstract][Full Text] [Related]
5. Incremental drug treatment cost in HIV-positive patients in industry-sponsored clinical trials.
Perrín RS; López FJ
Ann Pharmacother; 2008 Nov; 42(11):1586-91. PubMed ID: 18780807
[TBL] [Abstract][Full Text] [Related]
6. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
7. Has cost containment after the National Health Insurance system been successful? Determinants of Taiwan hospital costs.
Hung JH; Chang L
Health Policy; 2008 Mar; 85(3):321-35. PubMed ID: 17949848
[TBL] [Abstract][Full Text] [Related]
8. Drug Cost Avoidance in Prostate Cancer Clinical Trials.
Calvin-Lamas M; Portela-Pereira P; Rabuñal-Alvarez MT; Martinez-Breijo S; Martín-Herranz MI; Gómez-Veiga F
Actas Urol Esp; 2015 Nov; 39(9):553-7. PubMed ID: 26071987
[TBL] [Abstract][Full Text] [Related]
9. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
10. Estimating per patient funding for cancer clinical trials: an Ontario based survey.
Wright JR; Roche K; Smuck B; Cormier J; Cecchetto S; Akow M; Pilatzke S; Pritchard KI
Contemp Clin Trials; 2005 Aug; 26(4):421-9. PubMed ID: 15925548
[TBL] [Abstract][Full Text] [Related]
11. The costs of conducting clinical research.
Emanuel EJ; Schnipper LE; Kamin DY; Levinson J; Lichter AS
J Clin Oncol; 2003 Nov; 21(22):4145-50. PubMed ID: 14559889
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study on the utilization and cost of immunosuppressive agents among kidney transplant recipients in Taiwan: a 5-year review.
Lee EK; Tseng PL
Transplant Proc; 2008 Sep; 40(7):2214-7. PubMed ID: 18790196
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials: considerations for researchers and hospital administrators.
Uecke O; Reszka R; Linke J; Steul M; Posselt T
Health Care Manage Rev; 2008; 33(2):103-12. PubMed ID: 18360161
[TBL] [Abstract][Full Text] [Related]
14. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.
Chen LC; Schafheutle EI; Noyce PR
Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822
[TBL] [Abstract][Full Text] [Related]
15. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit.
Chuang LC; Sutton JD; Henderson GT
Hosp Pharm; 1994 Mar; 29(3):215-8, 221. PubMed ID: 10132696
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
17. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005.
Owusu-Edusei K; Tejani MN; Gift TL; Kent CK; Tao G
Sex Transm Dis; 2009 Jun; 36(6):395-9. PubMed ID: 19556934
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
19. Managing clinical grant costs.
Glass HE; Hollander K
Contemp Clin Trials; 2009 May; 30(3):221-6. PubMed ID: 19470309
[TBL] [Abstract][Full Text] [Related]
20. The cost of the district hospital: a case study in Malawi.
Mills AJ; Kapalamula J; Chisimbi S
Bull World Health Organ; 1993; 71(3-4):329-39. PubMed ID: 8324852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
